Kiora Pharmaceuticals Inc
NASDAQ:KPRX

  • LAST PRICE
    3.5550
  • TODAY'S CHANGE (%)
    -0.0132 (-0.3699%)
  • Bid / Lots
    3.5200/ 1
  • Ask / Lots
    3.5900/ 29
  • Open / Previous Close
    3.6800 / 3.5682
  • Day Range
    3.4700
    3.6800
  • 52 Week Range
    3.0000
    8.9820
  • Volume
    7,679

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 4 hours ago by Dow Jones
      Companies Mentioned: KPRX
      Tax and Other Receivables 363,706 2,049,965 ------------ Total Current Assets 31,652,637 4,738,031 Non-Current Assets: Property and Equipment, Net 62,609 8,065 Restricted Cash 4,520 4,267 Intangible Assets and In-Process R&D, Net 6,687,100 8,813,850 Operating Lease Assets with Right-of-Use 72,637 106,890 Other Assets 29,851 40,767 ------------ ------------ Total Assets $ 38,509,354 $ 13,711,870 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 660,415 $ 206,260 Accrued Expenses 1,714,211 1,380,666 Accrued Collaboration Credit 1,119,591 - Operating Lease Liabilities 33,447 47,069 Total Current Liabilities 3,527,664 1,633,995 Non-Current Liabilities: Contingent Consideration 4,133,008 5,128,959 Deferred Tax Liability 779,440 779,440 Operating Lease Liabilities 39,190 59,822 ------------ ------------ Total Non-Current Liabilities 4,951,638 5,968,221 ------------ ------------ Total Liabilities 8,479,302 7,602,216 ------------ ------------ Commitments and Contingencies (Note 8) Stockholders' Equity: Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at September 30, 2024 and December 31, 2023, respectively 4 4 Common Stock, $0.01 Par Value: 150,000,000 and 50,000,000 shares authorized; 3,000,788 and 856,182 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 267,679 77,078 Additional Paid-In Capital 168,996,195 153,192,228 Accumulated Deficit (139,158,620) (146,976,855) Accumulated Other Comprehensive Loss (75,206) (182,801) ------------ ------------ Total Stockholders' Equity 30,030,052 6,109,654 ------------ ------------ Total Liabilities and Stockholders' Equity $ 38,509,354 $ 13,711,870 ============ ============ CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ------------------------- 2024 2023 2024 2023 ---------- ---------- ---------- ----------- Revenue: Collaboration Revenue $ - $ - $16,000,000 $ - Grant Revenue - - 20,000 - Total Revenue - - 16,020,000 - ---------- ---------- ---------- ----------- Operating Expenses: General and Administrative 1,380,997 1,415,844 4,215,411 3,782,596 Research and Development 1,317,231 1,085,010 3,717,570 2,915,392 In-Process R&D Impairment 2,008,000 1,904,314 2,008,000 1,904,314 Change in Fair Value of Contingent Consideration (1,103,991) 1,513,400 (995,951) 1,865,945 ----------- Total Operating Expenses 3,602,237 5,918,568 8,945,030 10,468,247 ---------- ---------- ---------- Operating Income (Loss) (3,602,237) (5,918,568) 7,074,970 (10,468,247) ---------- ---------- ---------- ----------- Other Income (Expense), Net: Interest Income, Net 248,840 49,912 813,989 128,464 Other Income (Expense), Net (59,929) 105,715 (70,724) 94,493 Total Other Income, Net 188,911 155,627 743,265 222,957 ---------- ---------- ---------- ----------- Net Income (Loss) $(3,413,326) $(5,762,941) $ 7,818,235 $(10,245,290) ========== ========== ========== =========== Deemed Dividends from Warrant Reset Provision - (530,985) - (530,985) ========== ========== ========== =========== Net Loss Attributable to Common Shareholders $(3,413,326) $(6,293,926) $ 7,818,235 $(10,776,275) ========== ========== ========== =========== Net Income (Loss) per Common Share - Basic $ (0.81) $ (7.30) $ 2.08 $ (23.35) Weighted Average Shares Outstanding - Basic 4,214,950 789,656 3,757,467 438,687 ========== ========== ========== =========== Net Income (Loss) per Common Share - Diluted $ (0.81) $ (7.30) $ 1.91 $ (23.35) Weighted Average Shares Outstanding - Diluted 4,214,950 789,656 4,092,880 438,687 ========== ========== ========== =========== Other Comprehensive Income (Loss): Net Income (Loss) $(3,413,326) $(5,762,941) $ 7,818,235 $(10,245,290) Unrealized Gain on Marketable Securities 76,435 - 73,607 - Foreign Currency Translation Adjustments 94,094 (40,310) 33,988 (83,430) Comprehensive Income (Loss) $(3,242,797) $(5,803,251) $ 7,925,830 $(10,328,720) ========== ========== ========== =========== To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67320 To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229204

    • 4 hours ago by Dow Jones
      Companies Mentioned: KPRX
      Total Current Assets 31,652,637 4,738,031 Non-Current Assets: Property and Equipment, Net 62,609 8,065 Restricted Cash 4,520 4,267 Intangible Assets and In-Process R&D, Net 6,687,100 8,813,850 Operating Lease Assets with Right-of-Use 72,637 106,890 Other Assets 29,851 40,767 ------------ ------------ Total Assets $ 38,509,354 $ 13,711,870 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 660,415 $ 206,260 Accrued Expenses 1,714,211 1,380,666 Accrued Collaboration Credit 1,119,591 - Operating Lease Liabilities 33,447 47,069 Total Current Liabilities 3,527,664 1,633,995 Non-Current Liabilities: Contingent Consideration 4,133,008 5,128,959 Deferred Tax Liability 779,440 779,440 Operating Lease Liabilities 39,190 59,822 ------------ ------------ Total Non-Current Liabilities 4,951,638 5,968,221 ------------ ------------ Total Liabilities 8,479,302 7,602,216 ------------ ------------ Commitments and Contingencies (Note 8) Stockholders' Equity: Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at September 30, 2024 and December 31, 2023, respectively 4 4 Common Stock, $0.01 Par Value: 150,000,000 and 50,000,000 shares authorized; 3,000,788 and 856,182 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 267,679 77,078 Additional Paid-In Capital 168,996,195 153,192,228 Accumulated Deficit (139,158,620) (146,976,855) Accumulated Other Comprehensive Loss (75,206) (182,801) ------------ ------------ Total Stockholders' Equity 30,030,052 6,109,654 ------------ ------------ Total Liabilities and Stockholders' Equity $ 38,509,354 $ 13,711,870 ============ ============

    • 4 hours ago by Newsfile
      Companies Mentioned: KPRX

      Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include:

  • Oct 29, 2024

Peers Headlines